PLRX
Pliant Therapeutics, Inc. NASDAQ Listed Jun 3, 2020$1.16
+0.00%
vs $1.16
Mkt Cap $71.2M
52w Low $1.09
9.0% of range
52w High $1.87
50d MA $1.21
200d MA $1.35
P/E (TTM)
-0.6x
EV/EBITDA
—
P/B
0.4x
Debt/Equity
0.2x
ROE
-82.4%
P/FCF
-0.6x
RSI (14)
50.00
ATR (14)
$0.05
Beta
1.25
50d MA
$1.21
200d MA
$1.35
Avg Volume
478.6K
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
260 Littlefield Avenue · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | AMC | -0.42 | -0.35 | +16.7% | 1.33 | +0.0% | +6.0% | -4.3% | -3.0% | +1.5% | -3.8% | — |
| Nov 6, 2025 | AMC | -0.53 | -0.43 | +18.9% | 1.53 | -1.3% | +4.6% | +1.2% | +3.1% | +7.8% | -4.4% | — |
| Aug 7, 2025 | AMC | -0.62 | -0.71 | -14.5% | 1.68 | -7.1% | -1.2% | +2.4% | -1.2% | -4.8% | -1.2% | — |
| May 8, 2025 | AMC | -0.78 | -0.92 | -17.9% | 1.46 | -0.7% | -3.4% | +4.3% | -6.1% | -1.4% | +0.7% | — |
| Mar 3, 2025 | AMC | -0.99 | -0.82 | +17.2% | 1.38 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% | — |
| Nov 7, 2024 | AMC | -0.99 | -0.95 | +4.0% | 15.19 | +0.1% | -1.3% | -3.3% | -4.8% | -0.4% | -6.7% | — |
| Aug 7, 2024 | AMC | -0.85 | -0.92 | -8.2% | 12.54 | +0.5% | -2.2% | +0.2% | -3.5% | +3.5% | -2.8% | — |
| May 6, 2024 | AMC | -0.76 | -0.78 | -2.6% | 13.79 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% | — |
| Feb 27, 2024 | AMC | -0.81 | -0.69 | +14.8% | 17.21 | +4.6% | -3.4% | -4.5% | +4.2% | -0.9% | -1.0% | — |
| Nov 9, 2023 | AMC | -0.78 | -0.70 | +10.3% | 14.20 | +10.0% | -2.6% | -7.1% | +2.5% | +3.3% | -0.7% | — |
| Aug 9, 2023 | AMC | -0.73 | -0.70 | +4.1% | 18.18 | +1.2% | +3.3% | -4.0% | -0.1% | -0.4% | -4.1% | — |
| May 9, 2023 | AMC | -0.66 | -0.67 | -1.5% | 22.51 | +1.6% | +2.3% | -1.6% | -2.5% | +1.1% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 | Canaccord Genuity | Maintains | Hold → Hold | — | $1.41 | $1.41 | +0.0% | -4.3% | -3.0% | +1.5% | -3.8% | +3.9% |
| Mar 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.33 | $1.33 | +0.0% | +6.0% | -4.3% | -3.0% | +1.5% | -3.8% |
| Nov 7 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.53 | $1.51 | -1.3% | +4.6% | +1.2% | +3.1% | +7.8% | -4.4% |
| Oct 10 | JP Morgan | Downgrade | Neutral → Underweight | — | $1.54 | $1.48 | -3.9% | -4.5% | +1.4% | +1.3% | +4.0% | +5.1% |
| Aug 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.68 | $1.56 | -7.1% | -1.2% | +2.4% | -1.2% | -4.8% | -1.2% |
| Mar 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.70 | $1.65 | -2.9% | -0.6% | -4.1% | -2.5% | -1.9% | +2.6% |
| Mar 4 | RBC Capital | Maintains | Sector Perform → Sector Perform | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 4 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 4 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 4 | Needham | Downgrade | Buy → Hold | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $1.38 | $1.44 | +4.3% | -2.2% | +12.6% | +3.9% | +2.5% | -11.7% |
| Mar 3 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $3.44 | $3.10 | -9.9% | -59.9% | -2.2% | +12.6% | +3.9% | +2.5% |
| Feb 14 | Needham | Maintains | Buy → Buy | — | $3.29 | $3.15 | -4.3% | -7.6% | -2.0% | +0.7% | +0.3% | +2.3% |
| Feb 14 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $3.29 | $3.15 | -4.3% | -7.6% | -2.0% | +0.7% | +0.3% | +2.3% |
| Feb 10 | Citigroup | Downgrade | Buy → Neutral | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | Canaccord Genuity | Downgrade | Buy → Hold | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | JP Morgan | Downgrade | Overweight → Neutral | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | Needham | Maintains | Buy → Buy | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Feb 10 | RBC Capital | Downgrade | Outperform → Sector Perform | — | $7.79 | $3.02 | -61.2% | -60.6% | -15.0% | +4.2% | +21.0% | -7.6% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.19 | $15.21 | +0.1% | -1.3% | -3.3% | -4.8% | -0.4% | -6.7% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.84 | $12.01 | +1.4% | +1.4% | -1.1% | +6.1% | -0.8% | +1.0% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.28 | $12.05 | -1.9% | -3.5% | +3.5% | -2.8% | +4.2% | +1.0% |
| Aug 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $12.54 | $12.60 | +0.5% | -2.2% | +0.2% | -3.5% | +3.5% | -2.8% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $12.54 | $12.60 | +0.5% | -2.2% | +0.2% | -3.5% | +3.5% | -2.8% |
| Jul 16 | Needham | Maintains | Buy → Buy | — | $13.23 | $13.38 | +1.1% | +2.0% | -4.7% | -3.2% | -0.7% | +1.4% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.23 | $13.38 | +1.1% | +2.0% | -4.7% | -3.2% | -0.7% | +1.4% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.54 | $11.20 | -2.9% | -3.4% | +3.2% | -1.9% | +4.2% | +1.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.14 | $14.56 | +3.0% | +8.6% | +1.6% | -2.2% | -1.0% | -3.5% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| May 7 | RBC Capital | Maintains | Outperform → Outperform | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| May 7 | Needham | Maintains | Buy → Buy | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| May 7 | Oppenheimer | Maintains | Outperform → Outperform | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| May 7 | Citigroup | Maintains | Buy → Buy | — | $13.79 | $14.00 | +1.5% | +0.0% | -2.8% | +3.0% | +0.0% | -1.0% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $14.92 | $14.34 | -3.9% | -5.2% | +2.3% | -2.2% | -4.2% | -2.1% |
| Mar 12 | Needham | Maintains | Buy → Buy | — | $14.53 | $14.53 | +0.0% | +4.2% | +1.6% | -3.1% | +1.9% | -3.9% |
| Mar 5 | RBC Capital | Maintains | Outperform → Outperform | — | $16.39 | $16.59 | +1.2% | -1.0% | -3.3% | -0.3% | -0.6% | -6.6% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.21 | $18.00 | +4.6% | -3.4% | -4.5% | +4.2% | -0.9% | -1.0% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $17.21 | $18.00 | +4.6% | -3.4% | -4.5% | +4.2% | -0.9% | -1.0% |
| Feb 28 | RBC Capital | Maintains | Outperform → Outperform | — | $17.21 | $18.00 | +4.6% | -3.4% | -4.5% | +4.2% | -0.9% | -1.0% |
| Feb 5 | Needham | Maintains | Buy → Buy | — | $17.40 | $16.77 | -3.6% | -9.2% | +2.0% | -0.9% | +2.0% | +3.9% |
| Feb 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.40 | $16.77 | -3.6% | -9.2% | +2.0% | -0.9% | +2.0% | +3.9% |
| Nov 10 | RBC Capital | Maintains | Outperform → Outperform | — | $14.20 | $15.62 | +10.0% | -2.6% | -7.1% | +2.5% | +3.3% | -0.7% |
| Oct 4 | Needham | Maintains | Buy → Buy | — | $17.06 | $16.99 | -0.4% | -3.2% | +4.8% | +1.7% | -3.0% | +1.2% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.67 | $17.04 | +2.2% | -0.7% | -1.0% | +5.7% | -7.4% | +6.3% |
| Sep 27 | Needham | Maintains | Buy → Buy | — | $16.67 | $17.04 | +2.2% | -0.7% | -1.0% | +5.7% | -7.4% | +6.3% |
| Sep 15 | Needham | Maintains | Buy → Buy | — | $16.18 | $16.21 | +0.2% | -1.1% | +2.4% | +1.2% | -1.6% | -2.4% |
| Aug 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.55 | $16.61 | +0.4% | +0.2% | +0.7% | +1.0% | -0.5% | +0.1% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.17 | $17.17 | +0.0% | -0.9% | -0.2% | -2.8% | -1.6% | +1.8% |
No insider trades available.
8-K
Pliant Therapeutics, Inc. -- 8-K Filing
Pliant Therapeutics stockholders approved non-binding advisory support for executive compensation packages, allowing management to proceed with current pay structures without binding shareholder constraints.
Jun 11
8-K · 5.02
!!! Very High
Pliant Therapeutics, Inc. -- 8-K 5.02: Executive Change
Pliant Therapeutics director Pyott retired from the board due to personal reasons, with no operational disagreements, suggesting stable corporate governance and continuity.
Apr 17
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
PLRX disclosed a material event via 8-K filing, though specific details aren't provided in this summary, making it impossible to assess the stock impact without reviewing the complete filing.
Mar 30
8-K
Unknown — 8-K Filing
PLN-101095's positive Phase 1 data in difficult-to-treat tumors validates Pliant's integrin approach and accelerated Phase 1b expansion could create near-term catalysts, potentially justifying higher valuations.
Mar 11
8-K · 1.01
! Medium
Pliant Therapeutics, Inc. -- 8-K 1.01: Governance / Corporate
Pliant Therapeutics appointed Computershare Trust Co. as transfer agent, a routine administrative change that facilitates stock transfer and shareholder record-keeping operations.
Mar 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Tang Capital Management Llc | 6,143,132 | $7M | Added | Dec 2025 |
| 2 | Citadel Advisors Llc | 3,226,599 | $4M | Added | Mar 2026 |
| 3 | Blue Owl Capital Holdings Lp | 2,969,199 | $4M | — | Mar 2026 |
| 4 | Adar1 Capital Management, Llc | 2,585,126 | $3M | New | Mar 2026 |
| 5 | Acadian Asset Management Llc | 2,416,508 | $3M | Added | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 2,343,101 | $3M | New | Mar 2026 |
| 7 | Two Sigma Investments, Lp | 2,253,138 | $3M | Added | Mar 2026 |
| 8 | Monaco Asset Management Sam | 1,938,747 | $2M | Added | Dec 2025 |
| 9 | Renaissance Technologies Llc | 1,852,842 | $2M | Added | Mar 2026 |
| 10 | Woodline Partners Lp | 1,666,830 | $2M | Reduced | Mar 2026 |
| 11 | Bml Capital Management, Llc | 1,546,137 | $2M | — | Mar 2026 |
| 12 | Peapod Lane Capital Llc | 1,288,578 | $2M | Added | Mar 2026 |
| 13 | Millennium Management | 1,180,518 | $1M | Added | Mar 2026 |
| 14 | Morgan Stanley | 1,097,924 | $1M | Reduced | Dec 2025 |
| 15 | Ubs Group Ag | 1,057,954 | $1M | — | Mar 2026 |
| 16 | Marshall Wace, Llp | 995,973 | $1M | Reduced | Mar 2026 |
| 17 | Jpmorgan Chase & Co | 861,823 | $1M | Reduced | Mar 2026 |
| 18 | Jane Street Group, Llc | 653,774 | $798K | Added | Dec 2025 |
| 19 | Centiva Capital, Lp | 432,525 | $545K | Reduced | Mar 2026 |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 371,951 | $454K | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 17
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Ultra-Small Company Fund | 471,330 | $594K | Mar 2026 |
| 2 | iShares Micro-Cap ETF | 154,355 | $194K | Mar 2026 |
| 3 | Fidelity Extended Market Index Fund | 108,291 | $141K | Feb 2026 |
| 4 | Invesco RAFI US 1500 Small-Mid ETF | 113,474 | $137K | Jan 2026 |
| 5 | Fidelity Total Market Index Fund | 94,752 | $123K | Feb 2026 |
| 6 | Ultra-Small Company Market Fund | 82,300 | $104K | Mar 2026 |
| 7 | Fidelity Series Total Market Index Fund | 75,906 | $99K | Feb 2026 |
| 8 | Multi-Manager Small Cap Equity Strategies Fund | 55,129 | $72K | Feb 2026 |
| 9 | NVIT Small Cap Value Fund | 50,300 | $63K | Mar 2026 |
| 10 | SMALL CAP EQUITY FUND | 37,153 | $47K | Mar 2026 |
| 11 | Fidelity Nasdaq Composite Index Fund | 19,787 | $26K | Feb 2026 |
| 12 | Small Cap Core Fund | 8,053 | $10K | Mar 2026 |
| 13 | AST Small-Cap Equity Portfolio | 7,400 | $9K | Dec 2025 |
| 14 | AZL DFA U.S. Core Equity Fund | 2,307 | $3K | Mar 2026 |
| 15 | LVIP Dimensional U.S. Core Equity 1 Fund | 1,349 | $2K | Mar 2026 |
| 16 | LVIP Dimensional U.S. Core Equity 2 Fund | 1,160 | $1K | Mar 2026 |
| 17 | Knights of Columbus U.S. ALL CAP INDEX FUND | 299 | $362 | Jan 2026 |
Valuation
Market Cap
$71.2M
Enterprise Value
-$119.8M
P/E (TTM)
-0.63x
Forward P/E
—
PEG Ratio
0.02x
P/B
0.39x
P/S
—
P/FCF
-0.55x
EV/EBITDA
—
Shares Out
61.4M
Financials (TTM)
Revenue
$0
Net Income
-$113.2M
EBITDA
-$108.0M
Free Cash Flow
-$128.7M
Op Cash Flow
-$128.3M
EPS Basic
$-2.43
EPS Diluted
$-1.84
EPS Forward
$-1.51
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$225.2M
Total Liab.
$44.0M
Total Equity
$181.2M
Cash
$190.9M
LT Debt
$0
Book Value/Sh
$2.95
Debt/Equity
0.16x
Current Ratio
12.00
Quick Ratio
12.00
Returns & Growth
ROE
-82.4%
ROA
-66.3%
ROIC
-71.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
+30.0%
Price Returns
2W
+8.6%
1M
+3.3%
3M
-3.1%
6M
-21.7%
12M
-6.7%
Technicals
52W High
$1.87
52W Low
$1.09
50d MA
$1.21
200d MA
$1.35
RSI (14)
50.00
ATR (14)
$0.05
Beta
1.25
Avg Volume
479K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.00
High
$3.00
Low
$3.00
Median
$3.00
Data updated apr 26, 2026 7:57pm
· Source: financialmodelingprep.com